PharmAthene, Inc. (AMEX:PIP). Last Market Price: 2.48, Change: -0.26, % Change: (-9.49%). Shares trade in the range of 2.40 – 3.35 dollars. It has a market capitalization of 119.62M dollars, making it a Small Cap Stock and has 48.23M outstanding shares. The company has a beta of 1.46, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.64. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 43%. The company has a 52 week high of $ 4.96 and a 52 week low of $ 1.28. Average volumes of shares traded daily are 331,565. Volume traded in the last session was at 2,950,000, 8.90 times the average volume.
- PharmAthene, Inc. announced a significant decision in its litigation against SIGA Technologies in the Delaware Court of Chancery.
- PharmAthene filed the lawsuit against SIGA in December 2006 citing PharmAthene’s interest in ST-246, an orally available smallpox antiviral drug candidate.
- “We are extremely pleased with the Court’s decision”, stated Eric I. Richman, President and Chief Executive Officer. “This is an important victory for our Company and stockholders. This ruling, providing PharmAthene with 50% of worldwide net profits is transformative for the Company. As a result of this ruling, we will appropriately share in the financial success of ST-246 without any of the associated infrastructure and related expenses. The initial U.S. government contract for 1.7 million courses of smallpox antiviral therapy has already been awarded.”
For Q2 (Jun ’11), It had a Net profit margin of -37.92%, an Operating margin of -47.93%. Other Key stats and ratios are : Return on average assets of -38.96%, Return on average equity of -78.51%. The organization has an employee strength of 85
Consensus Recommendation is a Outperform.
Estimate for sales for the Quarter Ending Sep-11 show a mean of 8.03 million dollars, an estimate high of 10.50 million dollars and an estimate low of 6.60 million dollars. A year ago the figures stood at 10.50 million dollars.
Estimate for sales for the Quarter Ending Dec-11 show a mean of 10.03 million dollars, an estimate high of 13.00 million dollars and an estimate low of 6.60 million dollars. A year ago the figures stood at 10.50 million dollars.
Estimate for EPS for the Quarter Ending Sep-11 show a mean of -0.09 dollars, an estimate high of -0.08 dollars and an estimate low of -0.11 dollars. A year ago the figures stood at -0.14 dollars.
Estimate for EPS for the Quarter Ending Dec-11 show a mean of -0.07 dollars, an estimate high of -0.01 dollars and an estimate low of -0.13 dollars. A year ago the figures stood at -0.16 dollars.
Sales for Quarter Ending Jun-11 was estimated at 6.67 million dollars, however the actual sales figure stood at 6.43 million dollars, 0.24 million dollars less than estimates.
Sales for Quarter Ending Mar-11 was estimated at 6.33 million dollars, however the actual sales figure stood at 6.34 million dollars, 0 million dollars more than estimates.
 |
Post Written By: Ed Liston
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht. |
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.